MedTrace Logo

Study of FCN-098 in Patients With Advanced Solid Tumor

NCT05212987 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 43

Last updated 2022-01-28

No results posted yet for this study

Summary

A multi-center, open, single-arm phase I dose exploratory study to evaluate the safety, tolerability, pharmacokinetic characteristics and primary antitumor activity of FCN-098 in patients with advanced solid tumors.

Conditions

Interventions

DRUG

FCN-098

FCN-098 will be given orally in ascending doses starting at 40 mg Q12h until the maximum tolerated dose or recommended dose is reached.

Sponsors & Collaborators

  • Fochon Pharmaceuticals, Ltd.

    lead INDUSTRY

Principal Investigators

  • Hu Xi chun, MD · Fudan University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-12-31
Primary Completion
2024-05-08
Completion
2024-10-12

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05212987 on ClinicalTrials.gov